Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study EUROPEAN UROLOGY Parikh, D. A., Kaki, A., Williams, S. B. 2022; 81 (4): 429-430

View details for DOI 10.1016/j.ejso.2020.06.024

View details for Web of Science ID 000834990100028